1012 related articles for article (PubMed ID: 29693319)
1. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
2. Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin B
Biochem Pharmacol; 2021 Jul; 189():114039. PubMed ID: 32417188
[TBL] [Abstract][Full Text] [Related]
3. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
4. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
7. More than a messenger: Alternative splicing as a therapeutic target.
Black AJ; Gamarra JR; Giudice J
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194395. PubMed ID: 31271898
[TBL] [Abstract][Full Text] [Related]
8. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
10. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
11. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
[TBL] [Abstract][Full Text] [Related]
14. Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells.
Chang JG; Yang DM; Chang WH; Chow LP; Chan WL; Lin HH; Huang HD; Chang YS; Hung CH; Yang WK
PLoS One; 2011; 6(6):e18643. PubMed ID: 21694768
[TBL] [Abstract][Full Text] [Related]
15. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
[TBL] [Abstract][Full Text] [Related]
16. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
Bessa C; Matos P; Jordan P; Gonçalves V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
[TBL] [Abstract][Full Text] [Related]
17. Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.
Blijlevens M; Li J; van Beusechem VW
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065983
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and Regulation of Alternative Pre-mRNA Splicing.
Lee Y; Rio DC
Annu Rev Biochem; 2015; 84():291-323. PubMed ID: 25784052
[TBL] [Abstract][Full Text] [Related]
19. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
20. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
